Know Cancer

or
forgot password

Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling)
Both
Cancer

Thank you

Trial Information

Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease


Inclusion Criteria:



- Age 18 years or older

- Histologically or cytologically confirmed diagnosis of metastatic cancer

- No prior RT to currently involved sites

- Informed consent

- ECOG performance status < 2

- Intact organ and bone marrow function

- Obtained informed consent

Exclusion Criteria:

- Under 18 years of age

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

survival

Principal Investigator

Johnny Kao, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mount Sinai School of Medicine

Authority:

United States: Institutional Review Board

Study ID:

GCO 06-0906

NCT ID:

NCT00463060

Start Date:

January 2007

Completion Date:

Related Keywords:

  • Cancer

Name

Location

Mount Sinai School of MedicineNew York, New York  10029